J-WDMC Precision Therapeutics 

A Safe, Anti-Therapy Resistance, Tumor-Specific ADC-Immunotherapy Drug Maximizing Drug Loading in Tumor to Cure Currently Incurable Cancer 

Tumor-Specific ADC-Immunotherapy Drug with Zero Normal Tissue Binding

        Our invention “Tumor-Specific ADC-Immunotherapy Drug” specifically targets tumor, zero normal tissue binding: It is low toxicity to patients. Its low DLT (dose-limiting toxicity) can maximize drug dosing and therapy efficacy.  It can reduce cancer therapy-induced patient death, side-effects, complex diseases, lifespan shortening & secondary cancers.

          In comparison, current anticancer drugs/CAR-T targeting to CEACAM5, CEACAM6, Nectin-4, BCMA, CD19, CD20, CD30, CD38, CD40, CD44v6, CD47, CD70, CD73, CTLA-4, FRα, EGFR, Caprin-1, GPC3, Integrin, PD-L1, Trop2, CLDN18.2, PSMA, HER2, HER3, DLL3, TIGIT, PTK7, VEGF, c-Met, B7-H3, & B7-H4…etc., developing by AbbVie, AstraZeneca, BMS, Eli Lilly, Gilead, GSK, Johnson & Johnson, Merck, Pfizer, Roche, & Takeda…etc., show strong binding to normal tissues. These drugs can lead to severe organ damages and life-threatening toxicities. Also, their high DLTs limit drug dosing, thus have low therapy efficacies.

A Safe, Anti-Therapy Resistance, Tumor-Specific ADC-Immunotherapy Drug Binds Microtubules to Maximize Drug Loading in Tumor to Cure Currently Incurable Cancer

Current drugs often only give refractory late-stage cancer patients a few extra months before they die. Only 〜1% of administered drug doses accumulate in tumors, due to tumor efflux pumps expel drug, limited binding specificity, and tumor antigen mutation, making cancer hard to cure. Our drug breaks these limitations.

Current ADC drug antigens often are pure membrane ligands like EGFR that do not bind to cellular structure proteins, making them easily expelled into vessels by tumor cells, thus have low tumor-toxicity, damage normal organs, and drug resistance occur easily.

We developed a Safe, Ant-Therapy Resistance, Tumor-Specific ADC-Immunotherapy Drug binding to a tumor surface antigen & tumor microtubules, powered by a native anti-tumor M2 macrophages (M2-TAM) immunotherapy to cure refractory cancer.

# Breakthroughs

1. Tumor-specific targeting with zero normal tissue binding, eliminating toxic side effects.

2. Native anti-tumor cells, anti-M2-TAM, microtubule-binding maximizing tumor drug loading, and microtubule -attacking: No need for costly, complex genetic engineering, flexible linker, or multi-payload ADC design .

3. It is hard to design a ADC-toxin Linker that is stable in blood and cleavable in tumor cells. Our ADC easily resolves the problem. Inside tumor cells, our ADC binds to microtubules. the ADC toxin units naturally destroy microtubules and tumor cells. No need for designing a linker that is stable in blood while cleavable in tumor cells. This also ensures the toxins do not leak into blood, safeguarding the normal tissues. This also maximizes drug loading in tumor cells, blocking cancer therapy resistance.

4. Anti-Therapy Resistance: The antigen is essential for tumor cell proliferation (mitosis) and survival. Thus, tumor cells cannot mutate it to resist our drug.

5. As an antibody platform, it natively penetrates into bone marrow and lymphatic systems to kill Lymphoma amp; Multiple Myeloma tumor cells: It is A CAR-T alternative.

6. Integrates a native anti-M2-TAM (tumor-associated M2 macrophage) immunotherapy:

(1) Stop M2-TAM-induced regulatory T cells (Tregs) that protect tumors immunosuppressive shield.

(2) Reverse M2-TAM-induced CD8+ T cell dysfunction, reactivating them to kill tumor cells.

(3) Block M2-TAM-induced tumor CD47 Dont Eat Me Signal.

(4) Block M2-TAM-, MDSC-, and CAF-mediated tumor immunosuppression amp; their PD-L1/PD-1 tumor anti-T cell attack machinery.

(5) Stop M2-TAM-mediated tumor growth, drug resistance, angiogenesis, tissue remodeling 

#  Our drug only targets an antigen, yes it can directlty kill tumor cells, attack tumor's multiple immunosuppressive shields, unlock the gate of tumor drug resistance, maximize drug loading in tumor, and resist to tumor mutation escape at once. Thus, the drug has great potential to overcome refractory therapy resistance and cure currently incurable cancer. 

We filed patents in 2026 to get 20+7 years patent protection in most countries worldwide. Utility of our platform:

1.      Antibody-image-guided precision cancer surgery.

2.      Antibody-image-guided precision external beam radiation therapy (EBRT).

3.      Antibody-targeted agent for Boron Neutron Capture Therapy (BNCT).

4.      Antibody-targeted proton and heavy-ion therapy.

5.      Antibody-contrast-enhanced CT, MRI, & PET tumor imaging. 

6.      CAR-T therapy and CAR-NK therapy.

7.      Antibody-cell conjugates (ACCs).

8.      T-cell receptor-mimic (TCRm) antibodies.

9.      Bispecific T-cell Engagers (BiTEs): bispecific antibody for cancer immunotherapy.

10.  Degrader-Antibody Conjugates (DACs) for targeted protein degraders to kill tumors.

11.  Antibody-drug conjugates (ADCs), antibody radio-drug conjugate (ARC), peptide-drug conjugates.

12.  Cancer vaccines: DNA, RNA, protein, & peptide cancer vaccines.

13.  Nanoparticles for targeted magnetic hyperthermia therapy & in situ vaccination.

14. Antibody-targeted ultrasound cancer therapy.

15.  Antibody-image-guided precision Interventional Oncology Therapy.

Contact: jiangmwd@gmail.com